Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

On Gestagen Treatment of Advanced Prostatic Carcinoma

Details

Publisher
Informa UK Ltd
Copyright
© 1978 Informa UK Ltd
Subject
Original Article
ISSN
0036-5599
eISSN
1651-2065
D.O.I.
10.3109/00365597809179977
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

On Gestagen Treatment of Advanced Prostatic Carcinoma

Abstract

Depostat® treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study the clinical effect on prostatic cancer was, however, disappointing when compared to the well established effect of orchiectomy. The therapeutic failure of Depostat® might be related to the incomplete suppression of plasma testosterone compared to that observed after orchiectomy.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/informa-healthcare/on-gestagen-treatment-of-advanced-prostatic-carcinoma-9riFTaxNYu